NYMXF (Nymox Pharmaceutical) Total Liabilities: $7.43 Mil (As of Dec. 2024)


What is Nymox Pharmaceutical Total Liabilities?

Nymox Pharmaceutical NYMXF Total Liabilities is $7.43 Mil as of Dec. 2024.

Nymox Pharmaceutical's Total Liabilities for the quarter that ended in Dec. 2024 was $7.43 Mil.

Nymox Pharmaceutical's quarterly Total Liabilities increased from Dec. 2023 ($3.80 Mil) to Sep. 2024 ($6.92 Mil) and increased from Sep. 2024 ($6.92 Mil) to Dec. 2024 ($7.43 Mil).

Nymox Pharmaceutical's annual Total Liabilities increased from Dec. 2022 ($2.11 Mil) to Dec. 2023 ($3.80 Mil) and increased from Dec. 2023 ($3.80 Mil) to Dec. 2024 ($7.43 Mil).

Nymox Pharmaceutical Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical Total Liabilities Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 1.95 2.11 3.80 7.43

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 2.57 3.80 6.92 7.43

Nymox Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nymox Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.429+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.43

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=0.654--6.775
=7.43

Nymox Pharmaceutical's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.429+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.43

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=0.654--6.775
=7.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $7.43 Mil mean?
Nymox Pharmaceutical (NYMXF) has a Total Liabilities of $7.43 Mil as of Dec. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's Total Liabilities too high?
Nymox Pharmaceutical's current Total Liabilities is $7.43 Mil.
How does Nymox Pharmaceutical's Total Liabilities compare to LYRA and RNAZ?
Nymox Pharmaceutical's Total Liabilities of $7.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current Total Liabilities is $7.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current Total Liabilities of $7.43 Mil. The current Total Liabilities is $7.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current Total Liabilities is $7.43 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.